Clinical Trials

Multiple clinical trials investigate the therapeutic utility of flecainide across cardiac conditions, including atrial fibrillation, paroxysmal atrial fibrillation, general cardiac arrhythmias, and arrhythmogenic right ventricular cardiomyopathy. Encompassing Phase 2, Phase 4, and unassigned phases, these studies are sponsored by academic medical centers, university hospitals, and cardiovascular research societies such as the University of Rochester and the Hellenic Cardiovascular Research Society. Most recorded trials have a completed recruitment status, alongside a clinical trial with an unknown status.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04991896 Completed
Atrial Fibrillation|Arrhythmias Cardiac
AHEPA University Hospital|Skylitseio General Hospital
2020-01-01 --
NCT03685149 Completed
Arrhythmogenic Right Ventricular Cardiomyopathy
Wojciech Zareba|University of Rochester
2019-07-31 Phase 2
NCT03005366 Completed
Paroxysmal Atrial Fibrillation
David Filgueiras-Rama|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III|Hospital San Carlos Madrid
2017-01 Phase 4
NCT02190175 Completed
Atrial Fibrillation
Hellenic Cardiovascular Research Society
2014-06 --
NCT00945867 Unknown status
Atrial Fibrillation
Assaf-Harofeh Medical Center
2009-09 --

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Flecainide product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Flecainide selectively binds to and blocks fast voltage-gated sodium channels (Nav1.5), thereby inhibiting the rapid inward sodium influx during Phase 0 of the cardiac action potential. This reduction in sodium conductance slows cardiac impulse conduction and prolongs the refractory period, which suppresses hyper-excitable foci to maintain normal sinus rhythm in patients with atrial fibrillation and ventricular arrhythmias.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.